Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
Multiple myeloma (MM) is a malignant disease of the plasma cells representing approximately 10% of all hemato-oncological diseases. Detection of the disease is most probable at around 65 years of age, and the average survival of patients is estimated to be 5–10 years, specifically due to frequent re...
Main Authors: | Denisa Weiser Drozdkova, Katerina Smesny Trtkova |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/28/3/193 |
Similar Items
-
Disulfiram/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways
by: Yaqi Xu, et al.
Published: (2020-06-01) -
Disulfiram-induced polyneurophaty
by: Vujisić Slavica, et al.
Published: (2012-01-01) -
How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01) -
Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01) -
Disulfiram reaction
by: Banjac Nada, et al.
Published: (2019-01-01)